LIYE ZHANG

Dr. LIYE ZHANG

School of Life Science and Technology, ShanghaiTech University, Shanghai 201210, China
orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 August 2018 in Nature Methods
Verified
Journal Article
Closed access
PDF file
QLQiang Liu
Qiang Liu
JZJun Zheng
Jun Zheng
WSWeiping Sun
Weiping Sun
YHYinbo Huo
Yinbo Huo
LZLIYE ZHANG
LIYE ZHANG
MZMin Zhuang
Min Zhuang

14 December 2023 in Cancer Cell
Verified
Journal Article
Closed access
YSYunfan Sun
Yunfan Sun
PWPin Wu
Pin Wu
ZZZefan Zhang
Zefan Zhang
ZWZejian Wang
Zejian Wang
KZKaiqian Zhou
Kaiqian Zhou
JFJia Fan
Jia Fan

16 March 2016 in Scientific Reports
Verified
Journal Article
Open access
LZLIYE ZHANG
LIYE ZHANG
CYChih-Sheng Yang
Chih-Sheng Yang
XVXaralabos Varelas
Xaralabos Varelas
SMStefano Monti
Stefano Monti
RNA editing is a molecular event that alters specific nucleotides in RNA post-transcriptionally. RNA editing has the potential to impact a variety of cellular processes and is implicated in diseases such as cancer. Yet, the precise mechanisms by which RNA editing controls cellular processes are poorly understood. Here, we characterize sequences altered by RNA editing in patient samples from lymphoma, neuroblastoma and head and neck cancers. We show that A-to-I RNA editing sites are highly conserved across samples of the same tissue type and that most editing sites identified in tumors are also detectable in normal tissues. Next, we identify the significant changes in editing levels of known sites between tumor and paired “normal” tissues across 14 cancer types (627 pairs) from The Cancer Genome Atlas project and show that the complexity of RNA editing regulation cannot be captured by the activity of ADAR family genes alone. Our pan-cancer analysis confirms previous results on individual tumor types and suggests that changes of RNA editing levels in coding and 3′UTR regions could be a general mechanism to promote tumor growth. We also propose a model explaining how altered RNA editing levels affect microRNA-mediated post-transcriptional regulation of oncogenes and tumor-suppressors.

15 February 2022 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
LCLiping Chu
Liping Chu
YQYuxiu Qu
Yuxiu Qu
YAYang An
Yang An
LHLinjun Hou
Linjun Hou
JLJuewan Li
Juewan Li
WQWei Qi
Wei Qi
The methyltransferase Polycomb Repressive Complex 2 (PRC2), composed of EZH2, SUZ12, and EED subunits, is associated with transcriptional repression via tri-methylation of histone H3 on lysine 27 residue (H3K27me3). PRC2 is a valid drug target, as the EZH2 gain-of-function mutations identified in patient samples drive tumorigenesis. PRC2 inhibitors have been discovered and demonstrated anti-cancer efficacy in clinic. However, their pharmacological mechanisms are poorly understood. MAK683 is a potent EED inhibitor in clinical development. Focusing on MAK683-sensitive tumors with SMARCB1 or ARID1A loss, we identified a group of PRC2 target genes with high H3K27me3 signal through epigenomic and transcriptomic analysis. Multiple senescence-associated secretory phenotype (SASP) genes, such as GATA4, MMP2/10, ITGA2 and GBP1, are in this group besides previously identified CDKN2A/p16. Upon PRC2 inhibition, the de-repression of SASP genes is detected in multiple sensitive models and contributes to decreased Ki67+, extracellular matrix (ECM) reorganization, senescence associated inflammation and tumor regression even in CDKN2A/p16 knockout tumor. And the combination of PRC2 inhibitor and CDK4/6 inhibitor leads to better effect. The genes potential regulated by PRC2 in neuroblastoma samples exhibited significant enrichment of ECM and senescence associated inflammation, supporting the clinical relevance of our results. Altogether, our results unravel the pharmacological mechanism of PRC2 inhibitors and propose a combination strategy for MAK683 and other PRC2 drugs.

1 September 2020 in Molecular Therapy
Verified
Journal Article
Open access
YQYunbo Qiao
Yunbo Qiao
ZWZejian Wang
Zejian Wang
FTFangzhi Tan
Fangzhi Tan
JCJun Chen
Jun Chen
JLJianxiang Lin
Jianxiang Lin
GZGuisheng Zhong
Guisheng Zhong
Transcription growth factor β (TGF-β) signaling-triggered epithelial-to-mesenchymal transition (EMT) process is associated with tumor stemness, metastasis, and chemotherapy resistance. However, the epigenomic basis for TGF-β-induced EMT remains largely unknown. Here we reveal that HDAC1-mediated global histone deacetylation and the gain of specific histone H3 lysine 27 acetylation (H3K27ac)-marked enhancers are essential for the TGF-β-induced EMT process. Enhancers gained upon TGF-β treatment are linked to gene activation of EMT markers and cancer metastasis. Notably, dynamic enhancer gain or loss mainly occurs within pre-existing topologically associated domains (TADs) in epithelial cells, with minimal three-dimensional (3D) genome architecture reorganization. Through motif enrichment analysis of enhancers that are lost or gained upon TGF-β stimulation, we identify FOXA2 as a key factor to activate epithelial-specific enhancer activity, and we also find that TEAD4 forms a complex with SMAD2/3 to mediate TGF-β signaling-triggered mesenchymal enhancer reprogramming. Together, our results implicate that key transcription-factor (TF)-mediated enhancer reprogramming modulates the developmental transition in TGF-β signaling-associated cancer metastasis.

7 July 2023 in Science
Verified
Journal Article
Closed access
SLShiheng Liu
Shiheng Liu
HWHong Wang
Hong Wang
XLXiaorun Li
Xiaorun Li
FZFan Zhang
Fan Zhang
JLJane K.J. Lee
Jane K.J. Lee
Z. Hong ZhouZ. Hong Zhou
Z. Hong Zhou
In Trypanosoma brucei , the editosome, composed of RNA-editing substrate-binding complex (RESC) and RNA-editing catalytic complex (RECC), orchestrates guide RNA (gRNA)–programmed editing to recode cryptic mitochondrial transcripts into messenger RNAs (mRNAs). The mechanism of information transfer from gRNA to mRNA is unclear owing to a lack of high-resolution structures for these complexes. With cryo–electron microscopy and functional studies, we have captured gRNA-stabilizing RESC-A and gRNA-mRNA–binding RESC-B and RESC-C particles. RESC-A sequesters gRNA termini, thus promoting hairpin formation and blocking mRNA access. The conversion of RESC-A into RESC-B or -C unfolds gRNA and allows mRNA selection. The ensuing gRNA-mRNA duplex protrudes from RESC-B, likely exposing editing sites to RECC-catalyzed cleavage, uridine insertion or deletion, and ligation. Our work reveals a remodeling event facilitating gRNA-mRNA hybridization and assembly of a macromolecular substrate for the editosome’s catalytic modality.